A high performance liquid chromatography (HPLC) method has been developed for the simultaneous determination of four fluoroquinolones. The studied compounds have been enoxacin (ENO), norfloxacin (NOR), ofloxacin (OFLO) and enrofloxacin (ENRO). An isocratic elution method, using a mixture of tetrahydrofuran (8%) and phosphate buffer (pH 3.00, 30.0mM, 92%) as mobile phase, has been developed. Fluorimetric detection, exciting at 277nm, and multiemission scan (407nm for ENO, 444nm for both NOR and ENRO and 490nm for OFLO) has been used. Detection limits of 500, 14.7, 25.2 and 15.0ngmL(-1) for ENO, NOR, OFLO and ENRO, respectively, have been obtained. The proposed method has been satisfactorily applied to analyze NOR, OFLO and ENRO in human urine and serum samples.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.talanta.2005.07.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
N Engl J Med
January 2025
From Médecins Sans Frontières (L.G., F.V.), Sorbonne Université, INSERM Unité 1135, Centre d'Immunologie et des Maladies Infectieuses (L.G.), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (L.G.), and Epicentre (M.G., E. Baudin), Paris, and Translational Research on HIV and Endemic and Emerging Infectious Diseases, Montpellier Université de Montpellier, Montpellier, Institut de Recherche pour le Développement, Montpellier, INSERM, Montpellier (M.B.) - all in France; Interactive Development and Research, Singapore (U.K.); McGill University, Epidemiology, Biostatistics, and Occupational Health, Montreal (U.K.); UCSF Center for Tuberculosis (G.E.V., P.N., P.P.J.P.) and the Division of HIV, Infectious Diseases, and Global Medicine (G.E.V.), University of California at San Francisco, San Francisco; the National Scientific Center of Phthisiopulmonology (A.A., E. Berikova) and the Center of Phthisiopulmonology of Almaty Health Department (A.K.), Almaty, and the City Center of Phthisiopulmonology, Astana (Z.D.) - all in Kazakhstan; Médecins Sans Frontières (C.B., I.M.), the Medical Research Council Clinical Trials Unit at University College London (I.M.), and St. George's University of London Institute for Infection and Immunity (S.W.) - all in London; MedStar Health Research Institute, Washington, DC (M.C.); Médecins Sans Frontières, Mumbai (V. Chavan), the Indian Council of Medical Research Headquarters-New Delhi, New Delhi (S. Panda), and the Indian Council of Medical Research-National AIDS Research Institute, Pune (S. Patil) - all in India; the Centre for Infectious Disease Epidemiology and Research (V. Cox) and the Department of Medicine (H. McIlleron), University of Cape Town, and the Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (S.W.) - both in Cape Town, South Africa; the Institute of Tropical Medicine, Antwerp, Belgium (B. C. J.); Médecins Sans Frontières, Geneva (G.F., N.L.); Médecins Sans Frontières, Yerevan, Armenia (O.K.); the National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (N.K.); Partners In Health (M.K.) and Jhpiego Lesotho (L.O.) - both in Maseru; Socios En Salud Sucursal Peru (L.L., S.M.-T., J.R., E.S.-G., D.E.V.-V.), Hospital Nacional Sergio E. Bernales, Centro de Investigacion en Enfermedades Neumologicas (E.S.-G.), Hospital Nacional Dos de Mayo (E.T.), Universidad Nacional Mayor de San Marcos (E.T.), and Hospital Nacional Hipólito Unanue (D.E.V.-V.) - all in Lima; Global Health and Social Medicine, Harvard Medical School (L.L., K.J.S., M.L.R., C.D.M.), Partners In Health (L.L., K.J.S., M.L.R., C.D.M.), the Division of Global Health Equity, Brigham and Women's Hospital (K.J.S., M.L.R., C.D.M.), the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, (L.T.), and Harvard T.H. Chan School of Public Health (L.T.) - all in Boston; and the Indus Hospital and Health Network, Karachi, Pakistan (H. Mushtaque, N.S.).
Background: For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.
Methods: We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z).
This analysis assessed the relationship between the plasma concentrations of loperamide and its N-desmethyl loperamide meta- bolite (M1) and the potential QT interval prolongation at therapeutic and supratherapeutic doses. The exposure-response analysis was performed using the data from healthy adults participating in a randomized, double-blind, single-dose, four-way (placebo; loperamide 8 mg [therapeutic]; loperamide 48 mg [supratherapeutic]; moxifloxacin 400 mg [positive control]) crossover study. The electrocardiographic measurements extracted from 12-lead digital Holter recordings were time-matched to pharmacokinetic sampling of loperamide/M1.
View Article and Find Full Text PDFMoxifloxacin plus Cordyceps polysaccharide ameliorate intestinal barrier damage due to abdominal infection via anti-inflammation and immune regulation under simulated microgravity.
Life Sci Space Res (Amst)
February 2025
Department of General Surgery, the 306th Hospital of PLA-Peking University Teaching Hospital, Beijing 100101, PR China; Department of General Surgery, the Ninth Medical Center of PLA General Hospital, Beijing 100101, PR China. Electronic address:
Background: Currently, there is limited research on the impact of abdominal infection on intestinal damage under microgravity conditions. Cordyceps polysaccharide (CPS), the main active ingredient of Cordyceps, has demonstrated various pharmacological effects, including anti-inflammatory, antioxidant, and immunomodulatory properties. Moxifloxacin (MXF) is a fourth-generation quinolone antibiotic that is believed to have a dual regulatory effect on immune system activation and suppression.
View Article and Find Full Text PDFThe Changes in the Antibiotic Resistance of , , and in the Clinical Isolates of a Multiprofile Hospital over 6 Years (2017-2022).
J Clin Med
January 2025
Department of Medical Biology, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-368 Wroclaw, Poland.
The growing resistance of bacteria to antibiotics is a serious problem in health care. The present study aims to assess the drug resistance of , , and isolated from infections in a multispecialty hospital over a 6-year period. Identification and antimicrobial susceptibility testing were performed using the VITEK2 automated system (Biomerieux).
View Article and Find Full Text PDFCharacterization of Strains from Tonsillopharyngitis and Scarlet Fever Resurgence, 2023-FIRST Detection of M1 in Bulgaria.
Microorganisms
January 2025
Medical Faculty, Sofia University "St. Kliment Ohridski", 1407 Sofia, Bulgaria.
Recently a resurgence of has arisen, with concerns around the highly virulent M1 lineage. Our aim was to characterize , the immune responses it causes, and to determine the presence of the M1 lineage in Sofia, Bulgaria. In our study, the infections were confirmed by culture testing or rapid antigen test.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!